Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Technetium [99mTc]-H7ND in GI Malignancies and Healthy Volunteers
NCT06443710Phase 1Completed
- Sponsor
- Pharmadax Genesis
- Start
- May 2024
- Primary completion
- Nov 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of technetium Tc 99m H7ND in gastrointestinal cancer, sponsored by Pharmadax Genesis. Primary endpoint: Security Indicators. Started May 2024; status: completed.
02
Drugs
technetium Tc 99m H7ND
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT06443710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06443710.